Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
2(15%)
Results Posted
25%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
2
15%
Ph phase_2
4
31%
Ph phase_4
2
15%
Ph phase_3
4
31%

Phase Distribution

0

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
4(33.3%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
2(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

2

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(8)
Terminated(1)
Other(2)

Detailed Status

Completed8
Recruiting2
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
2
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (33.3%)
Phase 34 (33.3%)
Phase 42 (16.7%)
N/A2 (16.7%)

Trials by Status

recruiting215%
unknown215%
terminated18%
completed862%

Recent Activity

2 active trials
Showing 5 of 13
terminatedphase_2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

NCT04594694
recruitingphase_2

BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study

NCT02481245
recruiting

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

NCT06858332
completedphase_3

Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

NCT01654731
completedphase_3

Bezafibrate Plus Berberine in Mixed Dyslipidemia

NCT02548832
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04594694Phase 2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Terminated
NCT02481245Phase 2

BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study

Recruiting
NCT06858332

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Recruiting
NCT01654731Phase 3

Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Completed
NCT02548832Phase 3

Bezafibrate Plus Berberine in Mixed Dyslipidemia

Completed
NCT02984982Phase 4

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

Completed
NCT03649269Not Applicable

PC-300 Tea Effect on Triglyceride Levels

Completed
NCT02937012Phase 3

Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders

Unknown
NCT02398201Phase 2

A Study of Bezafibrate in Mitochondrial Myopathy

Completed
NCT02701166Phase 3

The Effect of Bezafibrate on Cholestatic Itch

Unknown
NCT02291796Phase 4

Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction

Completed
NCT00983788Phase 2

Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects

Completed
NCT01165060Not Applicable

The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13